Summit Therapeutics

mountain climb steep cliff climber struggle

Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF

If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.

Angus Liu May 27, 2026 11:25am

Summit, UCB-Candid, J&J—Fierce Pharma Asia

May 8, 2026 8:30am

Summit shares tumble on interim PD-1/VEGF trial miss

May 1, 2026 10:56am

Law Legal System Justice Crime concept Mallet Gavel Hammer and Scales on tabl

J&J alleges trade secret theft by former staffer linked to Summit

Mar 16, 2026 10:44am

AZ, Boehringer-Simcere, Daiichi and more—Fierce Pharma Asia

Jan 30, 2026 7:45am

Fierce Biotech

Pfizer lays out its PD-1xVEGF bispecific research strategy

Nov 11, 2025 11:43am